Chapter 1 : INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter 2 : EXECUTIVE SUMMARY

2.1. Market overview

2.1.1. Market segmentation

2.2. CXO Perspective

Chapter 3 : MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Porter's five forces analysis

3.3.1. Bargaining power of buyers
3.3.2. Bargaining power of suppliers
3.3.3. Thereat of new entrants
3.3.4. Threat of substitutes
3.3.5. Intensity of competitive rivalry

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Pre-existing medical conditions in Vietnam
3.4.1.2. Unavailability of substitutes

3.4.2. Restraint

3.4.2.1. Stringent Regulations

3.4.3. Opportunity

3.4.3.1. Unmet needs of Vietnamese Population

3.5. COVID-19 Impact Analysis

Chapter 4 : PLASMA FRACTIONATION MARKET, BY PRODUCT

4.1. Overview

4.1.1. Market size and forecast

4.2. Albumin

4.2.1. Key market trends and growth opportunities
4.2.2. Market size and forecast

4.3. Immunoglobulins

4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast

4.3.2.1. Subcutaneous Immunoglobulin

4.3.2.1.1. Market size and forecast

4.3.2.2. Intravenous Immunoglobulin

4.3.2.2.1. Market size and forecast

4.4. Coagulation factor VIII

4.4.1. Key market trends and growth opportunities
4.4.2. Market size and forecast

4.5. Coagulation factor IX

4.5.1. Market size and forecast

Chapter 5 : PLASMA FRACTIONATION MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Neurology

5.2.1. Market size and forecast

5.3. Hematology

5.3.1. Market size and forecast

5.4. Immunology

5.4.1. Market size and forecast

5.5. Critical care

5.5.1. Market size and forecast

5.6. Others

5.6.1. Market size and forecast

Chapter 6 : PLASMA FRACTIONATION MARKET, BY END USER

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospitals

6.2.1. Market size and forecast

6.3. Clinical research laboratories

6.3.1. Market size and forecast

Chapter 7 : COMPANY PROFILES

7.1. BAXTER INTERNATIONAL INC.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance

7.2. BIOTEST AG

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance

7.3. BIO PRODUCTS LABORATORY LTD.

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio

7.4. GETZ HEALTHCARE

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio

7.5. GRIFOLS SA

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance

7.6. KEDRION BIOPHARMA

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance

7.7. OCTAPHARMA

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio

7.8. NOVO NORDISK

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance

7.9. SANOVA HEALTHCARE

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio

7.10. SANQUIN BLOOD SUPPLY FOUNDATION

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance

7.11. TAKEDA PHARMACEUTICAL COMPANY LIMITED

7.11.1. Company overview
7.11.2. Company snapshot
7.11.3. Operating business segments
7.11.4. Product portfolio
7.11.5. Business performance
7.11.6. Key strategic moves and developments